Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Renin-angiotensin system inhibitor discontinuation in COVID-19 did not modify systemic ACE2 in a randomized controlled trial.
Rathkolb V, Traugott MT, Heinzel A, Poglitsch M, Aberle J, Eskandary F, Abrahamowicz A, Mueller M, Knollmueller P, Shoumariyeh T, Stuflesser J, Seeber I, Gibas G, Mayfurth H, Tinhof V, Schmoelz L, Zeitlinger M, Schoergenhofer C, Jilma B, Genser B, Hoepler W, Omid S, Karolyi M, Wenisch C, Oberbauer R, Zoufaly A, Hecking M, Reindl-Schwaighofer R. Rathkolb V, et al. Among authors: abrahamowicz a. iScience. 2023 Oct 5;26(11):108146. doi: 10.1016/j.isci.2023.108146. eCollection 2023 Nov 17. iScience. 2023. PMID: 37867935 Free PMC article.
The systemic renin-angiotensin system in COVID-19.
Reindl-Schwaighofer R, Hödlmoser S, Domenig O, Krenn K, Eskandary F, Krenn S, Schörgenhofer C, Rumpf B, Karolyi M, Traugott MT, Abrahamowicz A, Tinhof V, Mayfurth H, Rathkolb V, Mußnig S, Schmölz L, Ullrich R, Heinzel A, König F, Binder C, Bonderman D, Strassl R, Puchhammer-Stöckl E, Gorkiewicz G, Aberle JH, Jilma B, Wenisch C, Poglitsch M, Oberbauer R, Zoufaly A, Hecking M. Reindl-Schwaighofer R, et al. Among authors: abrahamowicz a. Sci Rep. 2022 Nov 22;12(1):20117. doi: 10.1038/s41598-022-24628-1. Sci Rep. 2022. PMID: 36418458 Free PMC article.
Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19-Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT).
Karolyi M, Pawelka E, Omid S, Koenig F, Kauer V, Rumpf B, Hoepler W, Kuran A, Laferl H, Seitz T, Traugott M, Rathkolb V, Mueller M, Abrahamowicz A, Schoergenhofer C, Hecking M, Assinger A, Wenisch C, Zeitlinger M, Jilma B, Zoufaly A. Karolyi M, et al. Among authors: abrahamowicz a. Front Pharmacol. 2022 Jul 22;13:870493. doi: 10.3389/fphar.2022.870493. eCollection 2022. Front Pharmacol. 2022. PMID: 35935856 Free PMC article.